Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
alecensa
roche registration gmbh - aletiniba hidrohlorīds - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - alecensa kā monotherapy ir norādīts pirmās līnijas ārstēšanai pieaugušiem pacientiem ar anaplastic limfomas kinase (sĀrms)-pozitīva uzlabotas nav maza šūnu plaušu vēzis (nsclc). alecensa kā monotherapy ir norādīts ārstēšanai pieaugušiem pacientiem ar alk‑pozitīvs papildu nsclc iepriekš apstrādātas ar crizotinib.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
lorviqua
pfizer europe ma eeig - lorlatinib - karcinoma, nesīkšūnu plaušas - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
lumeblue (previously known as methylthioninium chloride cosmo)
alfasigma s.p.a. - methylthioninium chloride - colorectal neoplasms; colonoscopy - citi diagnostiskie līdzekļi - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.